Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence

Archives of Virology

Volumn 156, Issue 10, 2011, Pages 1787-1794

  Andrabi, Raiees ^a   Choudhary, Alok K ^a   Bala, Manju ^b   Kalra, Rajesh ^a   Prakash, S S ^a   Pandey, R M ^a   Luthra, Kalpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD; CHEMISTRY; FEMALE; FOLLOW UP; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED; PHYSIOLOGY; PROTEIN MOTIF; VIROLOGY; VIRUS LOAD;

ADULT; AMINO ACID MOTIFS; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80053184382     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1053-5     Document Type: Article

References (43)

1. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
2. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
3. Stamatos NM, Mascola JR, Kalyanaraman VS et al (1998) Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol 72: 9656-9667.
4. Binley JM, Wrin T, Korber B et al (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
5. Li Y, Migueles SA, Welcher B et al (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-1034.
6. Burton DR, Pyati J, Koduri R et al (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
7. Binley JM, Lybarger EA, Crooks ET et al (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651-11668.
8. Stamatatos L, Morris L, Burton DR et al (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
9. Nickle DC, Rolland M, Jensen MA et al (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 3: e75.
10. Korber B, Gnanakaran S (2009) The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 4: 408-417.
11. Lynch RM, Shen T, Gnanakaran S et al (2009) Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses 25: 237-248.
12. Taylor BS, Hammer SM (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 359: 1965-1966.
13. Letvin NL (2002) Strategies for an HIV vaccine. J Clin Invest 110: 15-20.
14. McMichael AJ (2006) HIV vaccines. Annu Rev Immunol 24: 227-255.
15. Hemelaar J, Gouws E, Ghys PD et al (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-W23.
16. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
17. Thali M, Moore JP, Furman C et al (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
18. Dalgleish AG, Beverley PC, Clapham PR et al (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
19. Deng H, Liu R, Ellmeier W et al (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
20. Dragic T, Litwin V, Allaway GP et al (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
21. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
22. Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2: 1075-1082.
23. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444.
24. Zolla-Pazner S, Cohen SS, Krachmarov C et al (2008) Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372: 233-246.
25. Jiang X, Burke V, Totrov M et al (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 17: 955-961.
26. Almond D, Kimura T, Kong X et al (2010) Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 26: 717-723.
27. Zhu P, Liu J, Bess J Jr et al (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847-852.
28. Buchacher A, Predl R, Strutzenberger K et al (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359-369.
29. Muster T, Steindl F, Purtscher M et al (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
30. Zwick MB, Labrijn AF, Wang M et al (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
31. Krachmarov C, Pinter A, Honnen WJ et al (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79: 780-790.
32. Smith JD, Bruce CB, Featherstone AS et al (1994) Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10: 577-583.
33. Geffin RB, Scott GB, Melenwick M et al (1998) Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1. AIDS Res Hum Retroviruses 14: 579-590.
34. Sahni AK, Prasad VV, Seth P (2002) Genomic diversity of human immunodeficiency virus type-1 in India. Int J STD AIDS 13: 115-118.
35. Gorny MK, Revesz K, Williams C et al (2004) The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 78: 2394-2404.
36. Nokta M, Turk P, Loesch K et al (2000) Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count. Clin Diagn Lab Immunol 7: 412-416.
37. Piantadosi A, Panteleeff D, Blish CA et al (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83: 10269-10274.
38. Sather DN, Armann J, Ching LK et al (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769.
39. Muhlbacher M, Spruth M, Siegel F, Zangerle R, Dierich MP (1999) Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. Immunobiology 200: 295-305.
40. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL (1997) Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159: 279-289.
41. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y, Markowitz M, Ho DD, Moore JP (1998) HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 188: 233-245.
42. Haynes BF, Fleming J, St Clair EW et al (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
43. Nabel GJ (2005) Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 308: 1878-1879.